Miro Sciences Clears TGA Inspection Milestone Ahead Of Planned Crohn’s Trial
MSX: $0.041 +0.00% · MC: $16M
Miro Sciences says the TGA has completed its inspection of manufacturing partner Q-Gen, a step towards supplying StemSmart for a planned Phase 2 trial in treatment-resistant Crohn’s disease, subject to regulatory approvals. The company is targeting trial initiation by the end of 2026, following positive FDA feedback and the appointment of a clinical research organisation in October.

Comments